Trials / Recruiting
RecruitingNCT06793709
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Post-marketing Observational Study of Tasfygo Tablet 35 mg to Evaluate the Safety of Tasfygo in Patients With Unresectable Biliary Tract Cancer With FGFR2 Fusion Gene Positivity Who Progressed After Chemotherapy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to investigate the safety of Tasfygo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention | This is a non-interventional study. |
Timeline
- Start date
- 2025-07-10
- Primary completion
- 2032-11-20
- Completion
- 2032-11-20
- First posted
- 2025-01-27
- Last updated
- 2026-02-27
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT06793709. Inclusion in this directory is not an endorsement.